Steve Boatwright led a team at Gallagher & Kennedy in representing IsoRay, Inc. in its closing of a $8,250,000 registered direct offering with several institutional investors of 11,000,000 shares of its common stock at a price of $0.75 per share.
IsoRay, Inc. is a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck, and gynecological cancer.
Read IsoRay's press releases here:
IsoRay, Inc. Closes $8,250,000 Registered Direct Offering July 12, 2018
IsoRay Announces $8.25 Million Registered Direct Offering July 9, 2018